New Weight-Loss drug candidate put to the test in Early-Stage study
NCT ID NCT07338214
First seen Jan 16, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tested a single injection of petrelintide at different concentrations in 48 adults with a BMI of 27 or higher. The goal was to see how the body processes the drug and whether different concentrations affect safety. Participants were monitored for about 50 days. This was an early-stage study focused on drug behavior, not on weight loss or treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY/OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.